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Growth factor withdrawal from proliferating myoblasts induces the expression of muscle-specific genes essential for
myogenesis. By suppression subtractive hybridization (SSH), we have cloned a novel human cDNA that encodes a Cys3His
zinc finger protein named CHCR (Cys3His CCG1-Required). CHCR is related to Muscleblind (Mbl), a Drosophila
melanogaster protein required for terminal muscle differentiation. It also displays sequence similarity to EXP/MBNL, a
human Mbl protein that interacts with CUG expansions associated with the degenerative muscular disease, myotonic
dystrophy (DM1). This relationship with EXP/MBNL and Mbl suggests that CHCR also functions during muscle
differentiation. We have found that CHCR mRNA and protein levels decrease upon differentiation of mouse myoblast cells.
Constitutive expression of CHCR in C2C12 cells inhibits the induction of sarcomeric myosin heavy chain (MyHC) upon
serum deprivation. Induction of myogenin, an earlier marker of muscle differentiation, is inhibited to a lesser extent, while
expression of the cell cycle inhibitor, p21, remains unaffected. Loss of CHCR function by morpholino antisense
oligonucleotide treatment accelerates MyHC induction during differentiation of myoblast cells. These complementary
gain- and loss-of-function results suggest that CHCR is an inhibitor of myogenesis. CHCR represents the first muscleblind-
related protein that antagonizes, instead of promotes, muscle differentiation. © 2002 Elsevier Science (USA)
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Myogenesis is a highly ordered and regulated process that
can be temporally separated into four distinct events (An-
dres and Walsh, 1990). First, upon mitogen withdrawal, the
muscle specific, basic helix–loop–helix transcription factor
MyoD is activated, leading to the induction of myogenin
and other myogenic factors. Myogenin expression marks
the commitment of myoblasts to the differentiation path-
way (Sabourin and Rudnicki, 2000). Second, irreversible cell
cycle arrest is triggered by an increase in the cyclin-
dependent kinase inhibitor, p21 (Lassar et al., 1994; Walsh
and Perlman, 1997). Third, expression of terminal differen-
tiation markers, including sarcomeric MyHC and muscle
creatine kinase occurs in the differentiating cells (Clegg et
al., 1987). Finally, fusion of the differentiated myocytes
leads to the formation of multinucleated myotubes and
functional muscle. Perturbing any stage of this myogenic
program will result in compromised muscle development.
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218One protein that is required for the terminal stages of
muscle differentiation in Drosophila melanogaster is
Muscleblind (Mbl). Mbl was cloned in a genetic screen
designed to isolate genes that suppress the excessive pho-
toreceptor phenotype of sev-svp2 mutant flies (Begemann et
al., 1997). In addition to its role in photoreceptor formation,
Mbl is expressed late in larval development in the larynx,
pharyngeal, and visceral and somatic musculature, and is
required for terminal differentiation of these tissues (Artero
et al., 1998). Mbl mutant-flies are unable to properly orga-
nize the Z-bands in the sarcomeric apparatus resulting in
paralysis and embryonic lethality. A mammalian homo-
logue of Drosophila Mbl, EXP/MBNL, has been cloned as a
polypeptide that binds to CUG repeat expansions respon-
sible for the degenerative muscular disorder, myotonic
dystrophy (DM1) (Brook et al., 1992; Fu et al., 1992;
Mahedevan et al., 1992; Miller et al., 2000). The expression
of EXP/MBNL is induced as cells undergo muscle differen-
tiation. These findings, taken together, suggest that Mbl
and its mammalian homologue, EXP/MBNL, are required to
promote the muscle differentiation pathway.Our studies of cell cycle-related genes intersected with
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the EXP/MBNL muscle differentiation pathway described
above when we attempted to identify proliferation genes in
ts13 cells. ts13 cells are temperature-sensitive BHK-21
(baby hamster kidney) mutants that exhibit a proliferative
defect when grown at the nonpermissive temperature of
39.5°C (Talavera and Basilico, 1977). The mutant cells
arrest in late G1 due to a mutation in the CCG1/TAFII250
gene (Hayashida et al., 1994). While BHK-21 cells were
derived from the kidney, it has been demonstrated that they
are myofibroblasts that express a wide variety of muscle-
specific markers, such as troponin, MyHC, and MyoD
(Mayer and Leinwand, 1997; Van der Ven and Furst, 1998).
In addition, the muscle creatine kinase enhancer is equally
active in BHK-21 and C2C12 myoblast cells upon serum
deprivation. Myofibroblasts have been referred to as “cross-
dressers” in that they express a large number of muscle-
specific proteins but do not fuse into myotubes under
differentiation conditions (Walker et al., 2001). Therefore,
ts13 myofibroblast cells exhibit the unique trait of express-
ing both muscle-specific and nonmuscle proteins.
By suppression subtractive hybridization (SSH), we have
cloned a novel human cDNA encoding a Cys3His zinc
finger protein that we named CHCR (Cys3His CCG1-
Required). The coding region for CHCR was very recently
identified by another group in a database search for proteins
similar to MBNL (Fardaei et al., 2002). CHCR’s high degree
of sequence homology to Mbl led us to hypothesize that
CHCR plays a role in myogenesis. While Mbl is involved in
promoting muscle differentiation, CHCR appears to func-
tion in an opposing manner. We have found that constitu-
tive expression of CHCR in C2C12 mouse myoblasts
strongly inhibits the induction of MyHC, and to a lesser
extent, the earlier differentiation marker, myogenin. CHCR
does not, however, affect the induction of the cell cycle
inhibitor p21. Treatment of C2C12 cells with morpholino
antisense oligonucleotides, which reduced CHCR protein
levels, results in the acceleration of MyHC expression in
the presence of low serum. These data suggest that CHCR
differs from other members of the muscleblind family of
proteins by functioning as an inhibitor of terminal muscle
differentiation. Therefore, a delicate balance between posi-
tive and negative regulators is critical for the proper execu-
tion of the myogenic program.
MATERIALS AND METHODS
Tissue Cell Culture
Hamster ts13 cells were grown at 33.5°C, and the rescued ts13
cell line (ts13R3) was passaged at 39.5°C. The hamster cell lines,
HEK293 cells, and C2C12 mouse myoblast cell line were main-
tained in growth media (GM) consisting of DME and 10% FBS. For
differentiation assays, C2C12 cells were plated into collagen-
coated tissue culture plates in GM for 24 h. Growth medium was
then replaced with DME supplemented with 0 or 2% horse serum,
and 10 ng/ml insulin, 5.5 g/ml transferrin, and 10 ng/ml selenium
(DM). MM14 mouse myoblasts were grown exponentially in Ham’s
F10C nutrient medium supplemented with 15% horse serum and 3
ng/ml basic FGF as described by Neville et al. (1997). To initiate
differentiation, the growth medium was aspirated and cultures
were washed twice with saline G solution. Medium was then
replaced with F10C supplemented with 1.5% horse serum and 1
M insulin. The cells were allowed to differentiate for 2-4 days,
replacing media every 2 days as necessary. Collagen (C-7661) and
the insulin, transferrin, selenium supplement (I-3146) were pur-
chased from Sigma.
Suppression Subtractive Hybridization
ts13 cells were synchronized in G0 by serum starvation at
33.5°C. After the addition of media containing 10% FBS, cells were
maintained at 33.5°C (tracer) or shifted to 39.5°C (driver). Approxi-
mately 16–18 h post-serum addition, mRNA was harvested by
using the Fasttrack 2.0 Kit from Invitrogen. The driver pool was
subtracted from the tracer pool by using the technique of SSH as
described (Diatchenko et al., 1996). To control for heat shock
effects, ts13 and ts13R3 cells were serum starved at 33.5°C. Both
cell lines were then shifted to 39.5°C after serum addition, and
mRNA was harvested after 16–18 h. The driver pool (ts13) was
subtracted from the tracer (ts13R3).
Cloning of Human CHCR and Plasmid Constructs
Human HeLa gt11 cDNA library was purchased from Clontech.
The 5 end of the human CHCR cDNA was cloned from the human
gt11 cDNA library by using the gt11 reverse primer and N-term
30 mer (5-AAAGAACCAAGTGATGACATTTGATCGTT-3) in a
modified 5 RACE protocol in which the initial denaturing step was
carried out at 98°C for 10 min. The sequence of the 3 portion
of human CHCR was obtained from an EST (Accession No.
AA460149). Additional overlapping CHCR EST’s include Acces-
sion Nos. AA912517, AU157931, and AI970137. Primers 5-GAA-
TTCAATATGACGGCTGTCAATGTTGCC (CHCR ATG primer)
and 5-GGAATTCGTTACATCCTGAATCAACCCAAT-3 (CHCR
3 cloning primer) were used to PCR amplify a contiguous human
CHCR ORF from HEK293 cDNA synthesized by using oligo(dT)n
and random primers at a 1:1 ratio. Human CHCR cDNA, as an
EcoRI fragment, was subcloned into the EcoRI site of pBlueScript to
generate pBS-hCHCR. The eukaryotic expression vector CS2mt-
hCHCR was constructed by subcloning the EcoRV to XbaI frag-
ment of human CHCR from pBS-hCHCR between the StuI and
XbaI sites of CS2mt.
Establishment of mt-CHCR Expressing C2C12
Clonal Cell Lines
C2C12 cells, maintained in DME 10% FBS, were cotransfected
by calcium phosphate with 5 g of CS2mt or CS2mt-hCHCR
plasmid along with pNeo, a plasmid carrying the neomycin resis-
tance marker, at a ratio of 10:1. Forty-eight hours posttransfection,
cells were plated into DME  10% FBS and 1 mg/ml G418. After 2
weeks of section, G418 resistant colonies were isolated and
clonally expanded. Expression of mt-CHCR was determined by
Western blot analysis of whole cell extracts using the anti-myc
mAb 9E10. mt-CHCR-positive clonal cell lines were maintained in
DME  10% FBS in the presence 0.4 mg/ml G418.
Cloning of Mouse CHCR cDNA
Comparison of the human CHCR cDNA with mouse se-
quences deposited in the genomic shotgun Ensembl Trace database
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(EMBL-EBI and Sanger Institute) identified a number of genomic
sequences (trace file, G10P634271FF4.T0, mk2A-a4097b06.p1c,
G10P6011522FF9.T0, G10P678399FH2T0) that encode for portions
of mouse CHCR. These sequences were used to generate a mouse-
specific sense primer (5-CGGATCCAAGAGGGTGCACTTGAT-
TGCC-3) located 35 bp upstream of the initiator methionine, and
an antisense primer (5-CGGAATTCACACGGAGTTTCTTGT-
TGAGA-3) positioned 49 bp downstream of the termination
codon. These primers were used to amplify the entire coding region
of mouse CHCR by RT-PCR from 1 g total RNA isolated from the
mouse myoblast cell line, C2C12. RT-PCRs were incubated for 30
min at 50°C, followed by 35 cycle of: 15 s at 94°C, 20 s at 55°C, and
2 min at 72°C. The mouse CHCR sequence has been submitted
to GenBank (Accession No. AF466292). The mouse CHCR cDNA
was subcloned into the EcoRI site of the CS2 expression vector
(CS2mCHCR) and confirmed by DNA sequencing.
Generation of Polyclonal Antiserum
against Mouse CHCR
The carboxy-terminal 83 amino acids of the mouse CHCR
protein (residues 259 to 342) were subcloned between the BamHI
and EcoRI sites of the pGEX-KT expression vector and expressed as
a GST fusion protein in bacteria. Bacteria transformed with the
pGEX-KT C-term mCHCR expression plasmid were grown in LB
100 g/ml ampicillin at 25°C to OD600 of 0.2. Expression was
induced with the addition of 0.4 mM IPTG and proceeded for 24 h
at 30°C. Cell lysates prepared in STE buffer (50 mM Tris–HCl, pH
7.4, 150 mM NaCl, 1 mM EDTA) were incubated with 10 l of a
75% slurry of glutathione sepharose (Pharmacia) for 1 h at 4°C, and
bound proteins eluted with 20 mM glutathione in STE. Eluted
proteins were separated by SDS-PAGE and full-length GST-C-term
mCHCR was excised from the gel and used to immunize a rabbit
(Harlan BioProducts).
Retrovirus Infection of C2C12 Cells
Recombinant retrovirus, which produces a single message con-
taining the entire coding region for mouse CHCR upstream of an
internal ribosomal entry site followed by the coding region for GFP,
was constructed by Jason Fontenot in the laboratory of Dr. Alex-
ander Rudensky. C2C12 cells were plated into 24-well plates at a
density of 2  104 cells/well. The media was replaced with 1 ml of
retrovirus expressing either GFP or GFP and mouse CHCR (un-
tagged). C2C12 cells were infected by centrifugation of the plates at
2500g for 90 min at 37°C in the presence of 8 g/ml polybrene,
followed by incubation overnight at 33°C. The retrovirus-
containing medium was then replaced with growth media, and the
infected population was expanded to approximately 5  106 total
cells. GFP-positive cells were isolated by sterile FACS sorting.
Preparation of Cell Extracts and Western Blotting
Whole cell extracts were prepared by using a lysis buffer con-
taining 50 mM Tris–HCl (pH 7.5), 400 mM NaCl, 1% NP-40, 1 mM
DTT, and protease inhibitors. For Western blotting, lysates were
subjected to SDS-PAGE, and proteins were transferred onto nitro-
cellulose or PVDF membrane. Western blots were incubated with
the appropriate antibodies overnight at 4°C followed by either
alkaline phosphatase- or horseradish peroxidase-conjugated sec-
ondary antibody. Antibodies against sarcomeric MyHC (mAb
MF20) and myogenin (mAb F5D) were obtained from the Develop-
mental Studies Hybridoma Bank (DSHB) developed under the
auspices of the NICHD and maintained by the University of Iowa,
Department of Biological Sciences, Iowa City, IA 52242. The
anti-p21 antibody (C-19) was purchased from Santa Cruz Biotech-
nology and the anti--tubulin (mAb DM 1A) was purchased from
Sigma. The cell line for the anti-myc mAb 9E10 was kindly
provided by Dr. Randall Moon.
RT-PCR and Primers
Total RNA was isolated from MM14 and C2C12 mouse myo-
blast cell lines by using the Trizol Reagent from Gibco-BRL.
RT-PCR was performed by using the Superscript One-Step RT-PCR
with Platinum Taq kit (Gibco-BRL). The mouse CHCR primers
used in the RT-PCRs are 5-TCAGGGTCGGTGCACTC-3 and
5-AGAAATCAGAACCGGACCAT-3, and are located within
two adjacent exons. The sequences of the G3PDH primers are
5-ACCACAGTCCATGCCATCAC-3 and 5-TCCACCACCCT-
GTTGCTGTA-3. RT-PCRs using total RNA from C2C12 myo-
blasts as template, were performed as follows: 1 cycle at 50°C for 30
min; 1 cycle at 94°C for 2 min; 27 cycles at 94°C for 15 s, 55°C for
30 s, and 72°C for 45 s. Reactions using total RNA from MM14
myoblasts were performed with a similar PCR protocol, except that
the number of amplification cycles was increased from 27 to 35.
In Vitro Transcription/Translation Reactions
Complementary DNA for mouse MBNL was synthesized by
RT-PCR using primers based on sequence information available in
the GenBank database (Accession No. NM_020007) and subcloned
into the EcoRI site of the CS2 expression vector. In vitro protein
synthesis of mouse CHCR and mouse MBNL proteins was per-
formed by using the Promega TNT SP6 Coupled Reticulocyte
Lysate Kit. One microgram of CS2mCHCR or CS2mMBNL
plasmid DNA was used as template in transcription/translation
assays. The reactions were carried out in a 15-l volume and scaled
down proportionally to the manufacturer’s protocol. The sequence
of the mouse CHCR morpholino antisense oligonucleotide is
5-GCCAATTTGCTCTCAGTATGACAC-3. The standard con-
trol oligonucleotide was purchased from GeneTools.
In Vivo Treatment with Morpholino Antisense
Oligonucleotides
C2C12 cells were seeded into six well plates in growth media at
a density of 8  105 cells/well. The following day, the media was
replaced with DM (2% horse serum) containing 10 M mCHCR-AS
or a standard control morpholino available from GeneTool. The
cells were then immediately scraped off the plates in order to
deliver the oligonucleotides into the cells. Finally, the morpholino-
loaded cells were quickly transferred into collagen-coated six well
plates, allowed to attach in DM, and differentiated at 37°C for
2 days. Scrape delivery of the morpholino oligonucleotides was
carried out essentially as described by GeneTools (http://www.
gene-tools.com/).
RESULTS
Cloning of Human CHCR
ts13 cells are temperature-sensitive mutant BHK-21 cells
that arrest in the late G1 phase of the cell cycle at the
220 Squillace, Chenault, and Wang
© 2002 Elsevier Science (USA). All rights reserved.
nonpermissive temperature (39.5°C) due to a mutation in
the transcription factor CCG1/TAFII250 (Hayashida et al.,
1994). To identify genes regulating passage through G1, we
carried out a SSH screen with cDNA generated from ts13
cells grown at the permissive (33.5°C) and nonpermissive
temperatures. Because the cells were maintained at two
different temperatures, we wanted to eliminate changes in
gene expression that could be attributed to heat shock
effects. We therefore performed a second SSH screen using
pools of cDNA generated from two different cell lines,
which were both maintained at 39.5°C. The two cell lines
used were the mutant ts13 cells and a “rescued” ts13 cell
line (ts13R3), which constitutively expresses wild-type
CCG1/TAFII250 and no longer cell cycle arrests at 39.5°C.
We focused our efforts on a 340-bp, partial cDNA frag-
ment that was isolated in both screens and confirmed by
Northern blot analysis to be expressed only in permissively
grown ts13 cells (data not shown). The encoded protein
fragment was found to display significant homology to Mbl,
a D. melanogaster protein required for proper muscle de-
velopment (Artero et al., 1998). The region of Mbl that
aligns with this novel protein fragment contains an unusual
Cys3His zinc finger motif. We therefore named this newly
cloned protein CHCR for Cys3His CCG1-Required.
We then cloned the full-length human CHCR cDNA to
use for future functional studies (Fig. 1A). Using the ham-
ster CHCR cDNA fragment as a probe, we isolated an
800-bp human cDNA (1A1) that encodes the central portion
of human CHCR from a gt11 HeLa library. A modified
RACE procedure was used to isolate the missing 5 end of
the CHCR cDNA, including the initiator methionine and
79 bp of 5 untranslated region (UTR). A search of the
GenBank human EST (expressed sequence tags) database
identified several overlapping sequences exhibiting 100%
identity with the 1A1 human CHCR clone. Based on the
sequence of the ESTs and 5 RACE product, we designed a
primer set to amplify a cDNA encoding the complete
human CHCR open reading frame plus 491 bp of 3 UTR
from human embryonic kidney (HEK) 293 cells. When a
myc-epitope tagged version of the hCHCR cDNA was
transiently expressed in ts13 cells, a single polypeptide was
recognized by the anti-myc monoclonal antibody 9E10 only
in extracts prepared from transfected cells (Fig. 1B).
Human Muscleblind Protein Family
Human CHCR contains two pairs of Cys3His motifs,
unusual zinc finger domains, flanking a central proline-rich
region (Figs. 2A and 2B). The spacing between the cysteine
and histidine residues present in motifs 1 and 3 are identical
(CX7CX6CX3H and X  any amino acid), whereas motifs 2
and 4 have the unique spacing pattern of CX7CX4CX3H
that is not found in any other known Cys3His-containing
protein. In addition to displaying significant amino acid
identity (43%) with Drosophila Mbl (Fig. 3A), CHCR also
exhibits 45% similarity to the Caenorhabditis elegans
protein K02H8, thought to be the worm homologue of Mbl.
In humans, the EXP/MBNL and MBLL proteins are highly
related to CHCR (Figs. 3A and 3B). EXP/MBNL has been
implicated in muscle development, while the cellular func-
tion of MBLL is currently unknown. All three of the
mammalian proteins (CHCR, EXP/MBNL, MBLL) possess
significant amino acid identity with Mbl (45%), as well as
70% overall identity among each other, suggesting that
they represent a unique protein family. The Cys3His motifs
are highly conserved and are 90% identical between the
human Mbl family members. In fact, the spacing between
the cysteines and histidine in motifs 2 and 4 in CHCR is
unique to the vertebrate Mbl proteins further strengthening
the hypothesis that CHCR, EXP/MBNL, and MBLL com-
prise a family of mammalian Mbl homologues.
FIG. 1. Cloning and expression of full-length human CHCR
cDNA. (A) A linear diagram of the full-length human CHCR
cDNA. The positions, in nucleotides, of the initiation (ATG) and
termination (TGA) codons are indicated. The relative positions of
partial cDNAs from hamster (GIG-14), human (1A1) CHCR cD-
NAs, a human EST sequence, and the human 5 CHCR-PCR
product are shown. Primers used to generate the 5-end of CHCR
(N-term 30-mer) and the contiguous CHCR ORF (CHCR ATG
primer and CHCR 3 cloning primer) are indicated. (B) ts13 cells
were transiently transfected with 0 (no DNA) or 5 g (mt-CHCR) of
expression vector for mt-CHCR. Cell lysates were prepared ap-
proximately 48 h posttransfection. The lysates were electropho-
resed in 10% SDS-PAGE. The presence of mt-CHCR was deter-
mined by Western blotting with the anti-myc mAb 9E10. The size
of molecular weight markers, given in kDa, are shown on the left.
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CHCR mRNA Levels Decrease in Differentiating
MM14 and C2C12 Myoblasts
The expression of EXP/MBNL has been reported to in-
crease as replicating myoblasts are induced to differentiate
(Miller et al., 2000). The striking sequence similarity be-
tween CHCR and EXP/MBNL led us to investigate the
expression pattern of CHCR in proliferating and differenti-
ated MM14 and C2C12 mouse myoblast cells. MM14 cells
remain in the proliferative state when cultured in media
containing high serum and the anti-differentiation growth
factor, basic FGF, and can be induced to differentiate upon
removal of basic FGF and addition of insulin (Clegg et al.,
1987). C2C12, a second well-characterized mouse myoblast
cell line, will undergo differentiation when shifted from
high serum to media containing 0 or 2% horse serum and
insulin.
We observed by RT-PCR that CHCR mRNA is nearly
undetectable in differentiated MM14 cells and dramatically
reduced in differentiated C2C12 cells compared with their
proliferating counterparts (Fig. 4). Nearly 100% of the
MM14 cells and approximately 50% of C2C12 cells have
entered the late stage of muscle differentiation as deter-
mined by staining for sarcomeric MyHC, a biochemical
marker for the terminal stage of muscle differentiation (data
not shown). Expression of the housekeeping gene glyceral-
dehyde 3-phosphate dehydrogenase (G3PDH), used to con-
trol for mRNA input, was unchanged. These findings are in
sharp contrast to what has been described for EXP/MBNL.
The EXP/MBNL protein is undetectable in proliferating
C2C12 cells (Miller et al., 2000). During muscle differen-
tiation EXP/MBNL is not detected until day 2 and increases
to a maximal level by day 4. These data, taken together,
suggest that CHCR is expressed in a manner consistent
with a potential role in modulating the differentiation state
of myogenic cells.
Constitutive CHCR Expression in C2C12
Myoblasts Inhibits Myosin Heavy Chain
and Myogenin Induction, but Not p21,
During Muscle Differentiation
The downregulation of endogenous CHCR mRNA levels
during muscle differentiation led us to hypothesize that
completion of the myogenic program requires a reduction
in CHCR activity. According to this speculative hypoth-
esis, we predict that constitutive expression of CHCR in
myoblasts will inhibit muscle differentiation. To test this
hypothesis, we generated G418-resistant C2C12 clonal cell
lines that stably express myc-tagged human CHCR (mt-
CHCR) along with a number of control G418-resistantFIG. 2. CHCR is a novel human Cys3His containing protein. (A)
Schematic diagram of the human CHCR protein. The position and
consensus sequence for Cys3His motifs 1 and 3 (black boxes), and
motifs 2 and 4 (gray boxes) are provided, with the unique motif
spacing shown below. A central proline-rich region in CHCR also
is indicated. (B) Nucleotide and amino acid sequence of human
CHCR cDNA. The clone contains 79 bp of 5 UTR, 1005 bp of
coding sequence, and 491 bp of 3 UTR. The four Cys3His motifs
are boxed with the critical cysteine and histidine residues indicated
in bold. The sequence data are available from GenBank/EMBL/
DDBJ under Accession No. AF467070.
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clones not expressing mt-CHCR (Fig. 5A). Control (C7) and
mt-CHCR expressing C2C12 clones (E6) were plated on
collagen-coated plates in growth medium (GM) containing
0.4 mg/ml G418. The cells were induced to differentiate by
shifting to differentiation media (DM). As a measure of
muscle differentiation, the protein levels of sarcomeric
MyHC, a terminal differentiation marker, were monitored
by Western blot analysis. As expected, induction of MyHC
was detected in the control C2C12 clone as cells differen-
tiated over a 5-day period in DM (Fig. 5B, lanes 1–6).
Consistent with our hypothesis, the extent of MyHC in-
duction was compromised significantly in the mt-CHCR
expressing clone (Fig. 5B, lanes 7–12). The protein levels of
-tubulin, used to control for differences in protein loading,
remained unaltered indicating that mt-CHCR does not
have a global effect on gene expression (Fig. 5).
We have examined a total of six independently isolated
mt-CHCR expressing clones, all of which display compro-
mised MyHC induction in low serum (data not shown). By
contrast, no decrease in MyHC expression was observed
with any of the G418-resistant control C2C12 clones (total
of 5) analyzed in parallel. Therefore, we do not believe that
selection for differentiation-deficient C2C12 myoblasts has
occurred in our studies. Additional experiments designed to
further address this concern are described later.
“Commitment” to muscle differentiation requires the
expression of the bHLH protein, myogenin, and precedes
the terminal stages of myogenesis (Andres and Walsh,
FIG. 3. Sequence homology between CHCR and Muscleblind proteins. (A) The overall amino acid identity of Drosphophila Mbl, human
EXP/MBNL, and human MBLL with CHCR is given on the right. The position of Cys3His motifs 1 and 3 are shown in black, while the gray
boxes represent Cys3His motifs 2 and 4. (B) An amino acid alignment of the three human CHCR family members using the Multalin and
Boxshade programs is shown. Amino acid identities and similarities are indicated in black and gray, respectively.
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1990). Hindering the synthesis of cellular factors upstream
of MyHC in the muscle differentiation pathway could also
result in a dramatic decrease in MyHC protein levels. We
therefore examined the expression levels of the early myo-
genic marker, myogenin, in control and mt-CHCR express-
ing C2C12 cells after placing them in DM. Under condi-
tions that result in a sixfold reduction in MyHC protein
levels in mt-CHCR expressing C2C12 cells, only a twofold
decrease in myogenin was observed by western blot analy-
sis (Fig. 5C). These findings suggest that CHCR acts prior to
the terminal stages of muscle differentiation at approxi-
mately the time of myogenin induction.
Once myoblasts commit to become muscle tissue, they
must then withdraw from the proliferative cell cycle. This
event is marked by the induction of the cell cycle inhibitor,
p21, which is paramount for the differentiation pathway to
proceed to the terminal stages (Andres and Walsh, 1990).
We therefore performed Western blot analysis on mt-
CHCR-expressing and control C2C12 cells during the
course of differentiation to investigate whether CHCR
blocks p21 induction. Interestingly, the protein levels of the
cell cycle inhibitor p21 were unaffected by CHCR expres-
sion (Fig. 5D). These data indicate that CHCR function
precedes the terminal stage of muscle differentiation, but is
not required for cell cycle arrest.
Overexpression of Mouse CHCR in a Population of
C2C12 Cells Inhibits Myosin Heavy Chain Induction
To eliminate the possibility of isolating differentiation-
defective cells through clonal selection techniques, we
introduced mouse CHCR into a population of C2C12 myo-
blasts by retroviral infection. The ability to examine a
population of CHCR overexpressing cells, which maintain
a diverse genetic background, will avoid any experimental
pitfalls associated with traditional clonal selection. We also
decided to express the endogenous mouse protein in these
experiments to eliminate potential artifacts due to the
introduction of an epitope-tagged human protein into
mouse cells.
The first step was to clone and express the cDNA for
mouse CHCR (mCHCR). To this end, the human CHCR
sequence was used to perform a homology search of both
the GenBank EST database and the mouse Ensembl Trace
genomic shotgun database. While there was no EST se-
quence which included the initiator methionine of mouse
CHCR, a number of genomic sequences encoding several
portions of mouse CHCR fortuitously included the start
and stop codons. This sequence information allowed us to
generate a sense primer 35 bp upstream of the ATG and an
antisense primer 49 bp downstream of the translational
termination codon. By RT-PCR, a mouse CHCR cDNA
(1113 bp) encompassing the entire ORF (1029 bp) was
amplified from total RNA isolated from proliferating
C2C12 mouse myoblasts. Nucleotide sequencing and the
deduced amino acid sequence revealed that the mouse
protein is 342 amino acids and has a pI of 9. Like the human
CHCR protein, mouse CHCR possesses four characteristic
Cys3His, zinc finger motifs flanking a central proline-rich
region. The two CHCR proteins are 81% identical at the
amino acid level, varying only at the carboxyl terminus (Fig.
6). Having cloned mouse CHCR, the cDNA was used to
generate a recombinant retrovirus that produces a single
message including the coding region for mCHCR followed
by an internal ribosomal entry site upstream of the coding
FIG. 4. CHCR mRNA levels decrease in differentiated mouse
myoblasts. RT-PCR analysis was performed by using primers
designed against a 280-bp trans-exon region of the mouse CHCR
gene. Intron/exon boundaries for the mouse gene were identified by
aligning the mouse CHCR cDNA (Accession No. AF466292) with
shotgun genomic sequences deposited in the Ensembl Trace data-
base. Total RNA was harvested from proliferating MM14 and
C2C12 myoblast cells grown in GM, and differentiated MM14 and
C2C12 cells grown in DM for 4 (C2C12) or 5 (MM14) days. A total
of 0, 50, or 500 ng total RNA was used for RT-PCRs. RT-PCR of the
housekeeping gene, G3PDH, was performed with 0, 1, or 10 ng total
RNA to control for reverse transcriptase efficiency and RNA input.
PCR products were separated on 1.2% agarose gel and visualized by
ethidium bromide staining.
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region for the green fluorescence protein (GFP). The pres-
ence of GFP and mCHCR on the same mRNA molecule
allowed for the selection of a population of mouse CHCR
overexpressing cells by sterile FACS sorting for GFP-
positive cells. As a control, cells infected with a recombi-
nant retrovirus that only contains the GFP coding region
FIG. 5. Constitutive expression of CHCR in C2C12 mouse myoblasts inhibits myosin heavy chain, and myogenin but not p21 induction
during muscle differentiation. (A) Expression levels of mt-CHCR in C2C12 stable clones. Thirty micrograms of whole cell lysates from
G418 resistant control (lanes 1 and 2), and mt-CHCR-expressing (lanes 3 and 4) C2C12 clones were separated on 12% SDS–polyacrylamide
gel and subjected to Western blot analysis by using the anti-myc mAb 9E10. (B) Control (C7) and mt-CHCR-expressing (E6) C2C12 clones
maintained in growth media for 24 h were induced to differentiate by shifting the cells to differentiation media (DM). The expression of
MyHC was determined by immunoblotting whole cell lysates after 0 (lanes 1, 7), 1 (lanes 2, 8), 2 (lanes 3, 9), 3 (lanes 4, 10), 4 (lanes 5, 11),
and 5 (lanes 6, 12) days in DM using the anti-MyHC mAb MF20. The -tubulin levels also were monitored by Western blot analysis. The
relative amount of MyHC normalized for -tubulin was determined. (C) Same as (B), except lysates were immunoblotted with
anti-myogenin monoclonal antibody (mAb F5D) and quantified. (D) Control (C7) and mt-CHCR (E6)-expressing C2C12 clones were grown
in DME containing 10% FBS. After 24 h, cells were switched to DM and harvested after 0 (lanes 1, 4), 1 (lanes 2, 5), and 2 (lanes 3, 6) days.
Whole-cell extracts were immunoblotted with antibodies against p21 (C-19) and -tubulin (mAb DM 1A). The fold induction of p21 protein
levels, after normalization for -tubulin levels, are shown in graphic form. The data presented in (B–D) are from one representative
experiment and have been repeatedly observed and with several independently isolated clones.
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were sorted in parallel. To confirm expression of the un-
tagged mouse CHCR protein in the GFP/mCHCR cell
population, we generated a polyclonal antiserum against
the carboxy terminus of mouse CHCR. Western blot anal-
ysis using the anti-mCHCR antiserum revealed a single,
predominant 45-kDa band in GFP infected cells that is
presumed to represent the endogenous mCHCR (Fig. 7A).
The intensity of this band in the GFP/mCHCR cell popu-
lation was significantly increased, providing further evi-
dence that the 45-kDa polypeptide was indeed mCHCR,
and that mCHCR had been successfully overexpressed in
these cells (Fig. 7A).
Having established the overexpression of mCHCR in
C2C12 cells, we then tested the ability of the two popula-
tions of GFP cells to undergo differentiation by monitor-
ing MyHC levels (Fig. 7B). We observed that a significant
increase in MyHC levels was detected in the control in-
fected cells after 2 days in DM. No detectable induction was
observed with the pool of C2C12 cells that overexpress
mCHCR. It should be noted that the endogenous levels of
mCHCR were found to decrease in C2C12 cells after 2 days
in differentiation conditions, which parallels the reduction
in mRNA levels initially observed by RT-PCR. Therefore,
the results of a second independent method for overexpress-
ing mCHCR in C2C12 cells support our initial conclusion
that CHCR hinders the induction of MyHC and suggests
that, in contrast to Mbl, CHCR is an inhibitor of muscle
differentiation.
Morpholino Antisense Oligonucleotides Targeting
Mouse CHCR Accelerates MyHC Induction
in Differentiating C2C12 Mouse Myoblasts
To complement the gain-of-function studies described
above, we adopted a morpholino antisense oligonucleotide
strategy to reduce CHCR protein levels in C2C12 cells. To
carry out the loss-of-function studies, a morpholino anti-
sense oligonucleotide was designed that specifically targets
the 5 UTR and translational start codon of mouse CHCR
(mCHCR-AS), but not the highly related mouse MBNL
protein. The specificity and effectiveness of the morpholino
oligonucleotide was tested by adding increasing concentra-
tions of mCHCR-AS to an in vitro transcription/translation
system containing a mCHCR cDNA expression plasmid. In
the absence of any oligonucleotide, a single polypeptide
similar in size to the endogenous protein detected by the
anti-mCHCR antiserum was translated in the cell-free
system (Fig. 8A, lane 1). Addition of increasing concentra-
tions of the mouse CHCR specific morpholino oligonucle-
otide blocked translation, with 800 mM being 100% effec-
tive. No significant reduction in protein synthesis was
observed with 800 nM of the standard control oligonucleo-
tide (Fig. 8A, compare lanes 4 and 5). More importantly,
synthesis of mouse MBNL was unaffected at all concentra-
tions of morpholino antisense oligonucleotides examined
(Fig. 8A, lanes 6–10). These data suggest that mCHCR-AS
morpholino should serve as a selective and effective inhib-
itor of mCHCR protein synthesis in vivo.
FIG. 6. Amino acid alignment of the mouse and human CHCR proteins. Sequence alignment using the Multalin and Boxshade programs
illustrates the high level of similarity (88%, gray shading) and identity (81%, black shading) between the two proteins. The protein fragment
used for the production of the anti-mouse CHCR antiserum is indicated by the black bar.
226 Squillace, Chenault, and Wang
© 2002 Elsevier Science (USA). All rights reserved.
C2C12 cells, to be treated with morpholino antisense
oligonucleotides, were seeded into six well plates in GM.
The following day, the media was replaced with DM
containing 0 or 10 M mCHCR-AS or a standard control
morpholino oligonucleotide available from the manufac-
turer (GeneTool). The cells were then immediately scraped
off the plates to deliver the oligonucleotides and quickly
reattached to collagen-coated six-well plates in DM. After
48 h, the cells were harvested and analyzed by Western
blotting. The anti-mCHCR antiserum revealed a three- to
fourfold decrease in the protein levels of mCHCR in C2C12
cells treated with 10 M mCHCR-AS, but not in cells
exposed to the control oligonucleotide (Figs. 8B and 8C).
Expression of the -tubulin protein was unaffected by either
oligonucleotide. As assessed by light microscopy, the de-
crease in mCHCR expression in response to treatment with
the CHCR morpholino oligonucleotide did not appear to
affect the morphology of C2C12 cells when compared with
control oligonucleotide-treated cells. Next, we measured
the differentiation potential of mCHCR-AS- and control-
treated C2C12 cells by examining MyHC levels. We repeat-
edly observed that mCHCR-AS treatment increased the
levels of MyHC in differentiating C2C12 cells approxi-
mately 2.5-fold compared with cells exposed to the control
oligonucleotide (Fig. 9). The amount of -tubulin was
unaffected by the antisense oligonucleotides. Our data from
overexpression and antisense experiments are consistent
with the hypothesis that CHCR antagonizes the process of
muscle differentiation.
DISCUSSION
Using the technique of SSH, we have cloned a novel
human cDNA that encodes a Cys3His zinc finger protein
that we have named CHCR, for Cys3His CCG1-Required.
CHCR displays significant amino acid identity to the Mbl
family of proteins that are involved in muscle development.
The observation that CHCR mRNA levels decrease in
FIG. 7. Overexpression of mCHCR in a population of C2C12 cells
inhibits MyHC induction. (A) C2C12 cells infected with retrovirus
that expresses GFP or GFP and mCHCR were subjected to sterile
FACS sorting for GFP positive cells. Lysates prepared from the
sorted cells were subjected to anti-mCHCR and anti-GFP immu-
noblotting. The 45-kDa band detected in the control infected cells
() represents endogenous mouse CHCR and is expressed at
significantly higher levels in the mCHCR infected population
(mCHCR). Equal amounts of GFP are expressed in the two popu-
lations. (B) The mCHCR overexpressing (mCHCR) and control ()
populations of sorted C2C12 cells were shifted to DM for 2 days,
and the level of MyHC, mCHCR, and -tubulin was determined by
Western blotting.
FIG. 8. mCHCR morpholino antisense oligonucleotide specifi-
cally inhibits translation of mouse CHCR protein in vitro and in
vivo. (A) Mouse CHCR and mouse MBNL were translated in vitro
in the presence of biotinylated lysine-tRNA and indicated concen-
trations of mouse CHCR (mCHCR) or control (Ctrl) antisense
oligonucleotide using the TNT SP6 Quick Coupled Transcription/
Translation System (Promega). Reactions were subjected to SDS-
PAGE, and translated proteins were detected with streptavidin-
conjugated horseradish peroxidase followed by chemiluminescence
(Transcent Non-radioactive Translation Detection System; Pro-
mega). (B) C2C12 myoblasts were seeded into DME  10% FBS.
Ten micromolar of mCHCR-AS or control (Ctrl) antisense oligo-
nucleotide was scrape delivered, and the cells were allowed to
recover overnight in GM. Media was then changed to DME
containing 2% horse serum and insulin (DM) to induce cells to
differentiate. After 48 h, the amount of mouse CHCR in whole cell
lysates was determined by Western blotting with an anti-mouse
CHCR antibody, quantitated, and normalized for -tubulin levels.
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differentiated mouse myoblasts led us to hypothesize that
CHCR is an inhibitor of the myogenic program. We have
found that constitutive expression of CHCR in C2C12
mouse myoblasts inhibits the induction of the muscle
specific genes, MyHC and myogenin, during muscle differ-
entiation, while loss of CHCR function, by treatment with
antisense oligonucleotides, accelerates the expression of
MyHC. These two complementary findings support the
hypothesis that CHCR is a negative regulator of muscle
differentiation. Therefore, CHCR represents a novel mem-
ber of the muscleblind family that antagonizes, instead of
promotes, the process of myogenesis. These new pieces of
evidence suggest that CHCR and its human Mbl homo-
logue, EXP/MBNL, function as opposing forces, both con-
tributing to the controlled induction of terminal muscle
differentiation.
The functional importance of Mbl can be inferred from
conservation of this protein throughout evolution. Se-
quence analysis reveals the existence of a single Mbl
homologue in C. elegans and one Mbl gene in Drosophila.
Interestingly, this family expands to three members in
mammals where homologues of CHCR, EXP/MBNL, and
MBLL can be identified in EST and genomic databases for
mouse, rat, bovine, and humans. The complexity of mam-
malian organisms requires a staggering number of regula-
tory proteins to control the vast array of signaling pathways
supporting vertebrate life. The evolution of two additional
Mbl proteins in vertebrates may reflect the need for regu-
lation or modulation of Mbl function. This hypothesis is
supported by the discovery that CHCR expression precedes
the appearance of EXP/MBNL during muscle differentia-
tion, providing CHCR the opportunity to negatively regu-
late myogenesis.
Multiple pathways that regulate the activity of myogenic
regulatory factors (MRFs) and MEF-2 family members in-
fluence skeletal muscle differentiation (Perry and Rudnicki,
2000; Puri and Sartorelli, 2000). The basic helix–loop–helix
MRFs (MyoD, Myf5, myogenin, and MRF4/herculin) func-
tion in concert with the E2A and MEF-2 family of transcrip-
tion factors to drive myogenic gene expression. MEF-2
family members synergize with MRFs/E2A heterodimers to
activate muscle-specific gene transcription. Genetic studies
in Drosophila have placed Mbl downstream of Dmef2, a
MEF-2 protein, in the muscle differentiation pathway (Ar-
tero et al., 1998). It is thus possible that, by constitutively
expressing CHCR in C2C12 cells, we hindered the function of
mouse MEF-2 proteins in promoting muscle differentiation.
The presence of four Cys3His motifs in CHCR also may
provide some insight into its mechanism of action. Such
motifs, first identified in the mRNA binding protein, tris-
tetraprolin, have been proposed to represent unusual zinc
finger domains (DuBois et al., 1990; Lim et al., 1987).
Cys3His motifs are found in a growing number of proteins
present in a wide range of organisms, including trypano-
somes, yeast, worms, mice, and humans. Although mem-
bers of this family are involved in a variety of cellular
processes, from proliferation to differentiation, many have
been shown to possess RNA binding activity (Anderson et
al., 1993; Bai and Tolias, 1998; Lai et al., 2000). Tristetra-
prolin, the most well-characterized Cys3His containing
protein, binds to the AU-rich element of the tumor necrosis
factor alpha mRNA and subsequently targets the message
for degradation (Carballo et al., 1998; Lai et al., 1999).
Mutagenesis of a single cysteine residue in either of two
Cys3His zinc fingers completely abolishes RNA binding
(Lai et al., 1999). In Caenorhabditis elegans, the Cys3His
zinc finger protein PIE-1 is a regulator of maternal and
zygotic gene expression in the developing embryo (Tenen-
haus et al., 2001). Mutation of the second Cys3His zinc
finger reduces PIE-1-mediated activation of protein expres-
sion from the nos-2 maternal RNA. It has been suggested
that PIE-1 affects maternal RNA expression by directly
binding RNA. The CHCR-related Cys3His-containing
protein, EXP/MBNL, binds preferentially to the double-
stranded RNA hairpins formed by CUG expansions (Miller
et al., 2000; Michalowski et al., 1999; Napierala and
Krzyzosiak, 1997; Tian et al., 2000). Based on this evidence,
FIG. 9. Treatment with mCHCR antisense oligonucleotide accel-
erates MyHC expression in differentiating C2C12 mouse myo-
blasts. (A) C2C12 myoblasts, seeded into DME  10% FBS, were
treated with mCHCR-AS or control (Ctrl) antisense oligonucleo-
tide as described in Fig. 8B and were induced to differentiate. After
48 h under differentiation conditions, cell lysates were prepared,
and the levels of myosin heavy chain (MyHC) and -tubulin were
determined by Western blotting. The results from one representa-
tive experiment are shown (B). The relative amounts of MyHC
normalized for -tubulin levels from three independent experi-
ments were determined and are shown in the graph with standard
errors indicated.
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CHCR may regulate muscle-specific gene expression by
interacting with the transcripts of target genes. It will be of
interest to examine the RNA-binding capability of CHCR
both in vitro and in vivo and identify RNAs that associate
with the CHCR protein.
DM1 is characterized by an expansion of CTG repeats in
the 3 UTR of the dystrophic myotonic protein kinase
(DMPK) gene (Brooks et al., 1992; Fu et al., 1992; Ma-
hadevan et al., 1992; Meola, 2000). Three different models
have been suggested to explain how expansions in the 3
UTR can lead to the dominantly inherited DM1 disease.
One model is that the triplet repeat expansions produce a
gain-of-function RNA molecule that impairs nucleocyto-
plasmic mRNA export and/or sequesters nuclear factors
required for proper muscle formation and maintenance
(Davis et al., 1997; Mankodi et al., 2000, 2001; Timchenko
et al., 1996). EXP/MNBL colocalizes with the CUG expan-
sions found in mutant DMPK transcripts in DM1 cells, but
not with DMPK mRNA in normal cells (Fardaei et al.,
2001). It has been proposed that the aberrant recruitment
and sequestration of EXP proteins to the large CUG expan-
sions in the DMPK transcript contributes to the DM1
phenotype. Very recently, CHCR was also found to colocal-
ize with expanded repeat transcripts in the nuclei of DM1
cells (Fardaei et al., 2002). These findings suggest that both
CHCR and MBNL may play a role in the development of
the diseased state.
We have cloned a novel cDNA that encodes a Cys3His-
containing protein and provided evidence that it functions
as an inhibitor of muscle differentiation. Although we have
focused on CHCR’s role in myogenesis, tissue expression
analysis of CHCR mRNA levels in the adult mouse indicate
that the message for CHCR is not restricted to the muscle
lineage (R.M.S. and E.H.W., unpublished data). CHCR may
thus play a general role in regulating the differentiation
programs of mammalian cells.
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